Bleomycin clinical trials
Bleomycin is named as an intervention in 20 current clinical trials in our Netherlands, Canada, Italy, Mexico, China, Israel, Spain, Belgium, Portugal, Australia, France, Denmark, Germany, India, Poland, Egypt, Ireland, UK, USA, Czechia, Brazil, South Korea, Sweden, Japan and Switzerland registers. 12 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Beihua Kong (2). The most-studied condition is Hodgkin Lymphoma.
Where Bleomycin is approved
All regulators →Of the three regulators tracked here, the first to approve Bleomycin was the US, on 31 Jul 1973. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Bleomycin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Bleomycin works
All drug targets →- AIDSPhase 3
- Kaposi's sarcomaPhase 3
- Classic Hodgkin lymphomaPhase 3
- Diffuse large B-cell lymphomaPhase 3
- Head and neck cancerPhase 3
- Malignant sex cord stromal tumor of ovaryPhase 3
- Non-Hodgkin lymphomaPhase 3
- Nongerminomatous germ cell tumorPhase 3
- OsteosarcomaPhase 3
- Peripheral T-cell lymphoma, not otherwise specifiedPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6067492, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Bleomycin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Bleomycin
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Bleomycin
35 conditionsAll 35 conditions
| Condition (as registered) | Trials |
|---|---|
| Hodgkin Lymphoma | 3 |
| Ovarian Neoplasms | 2 |
| Ovarian Cancer | 2 |
| Germ Cell Tumor | 2 |
| Lymphoma | 2 |
| Hodgkin Lymphoma, Adult | 1 |
| Ovarian Germ Cell Cancer | 1 |
| Lymphatic Malformation | 1 |
| Plantar Wart | 1 |
| Ovarian Sex Cord Stromal Tumor | 1 |
| Vulvar Cancer | 1 |
| Vascular Malformations | 1 |
| Toxicity Due to Chemotherapy | 1 |
| Cardiovascular Morbidity | 1 |
| Cancer, Treatment-Related | 1 |
| Testicular Cancer | 1 |
| Seminoma | 1 |
| Quality of Life | 1 |
| De-escalation | 1 |
| Cutaneous Metastasis | 1 |
| Cutaneous Malignant Mixed Tumor | 1 |
| Bleomycin Adverse Reaction | 1 |
| Electrochemotherapy | 1 |
| Ann Arbor Stage I Hodgkin Lymphoma | 1 |
| Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma | 1 |
| Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma | 1 |
| Ann Arbor Stage IA Hodgkin Lymphoma | 1 |
| Childhood Extracranial Germ Cell Tumor | 1 |
| Extragonadal Embryonal Carcinoma | 1 |
| Malignant Germ Cell Tumor | 1 |
| Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | 1 |
| Ann Arbor Stage IIB Hodgkin Lymphoma | 1 |
| Ann Arbor Stage IIIB Hodgkin Lymphoma | 1 |
| Ann Arbor Stage IVA Hodgkin Lymphoma | 1 |
| Ann Arbor Stage IVB Hodgkin Lymphoma | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Beihua Kong | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| National Cancer Institute (NCI) | 2 |
| University College, London | 1 |
| Merck Sharp & Dohme LLC | 1 |
| State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | 1 |
| West China Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 1 |
| Istituto Ortopedico Rizzoli | 1 |
| University Medical Center Groningen | 1 |
| Sahlgrenska University Hospital | 1 |
| Julie Gehl | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| University of Sydney | 1 |
+ 2 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Bleomycin trials
How many clinical trials are testing Bleomycin?
20 current trials in our Netherlands, Canada, Italy, Mexico, China, Israel, Spain, Belgium, Portugal, Australia, France, Denmark, Germany, India, Poland, Egypt, Ireland, UK, USA, Czechia, Brazil, South Korea, Sweden, Japan and Switzerland registers name Bleomycin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Bleomycin trials recruiting patients?
Yes. 12 of the 20 trials are recruiting: 1 with sites in Netherlands, 3 with sites in Canada, 2 with sites in Italy, 2 with sites in Mexico, 3 with sites in China, 2 with sites in Israel, 1 with sites in Spain, 1 with sites in Belgium, 1 with sites in Portugal, 3 with sites in Australia, 2 with sites in Denmark, 2 with sites in India, 1 with sites in Egypt, 1 with sites in Ireland, 1 with sites in Sweden and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Bleomycin clinical trials?
Beihua Kong (2), European Organisation for Research and Treatment of Cancer - EORTC (2), National Cancer Institute (NCI) (2) and University College, London (1), among 17 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Bleomycin clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Bleomycin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bleomycin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bleomycin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.